ArticleClinical and experimental pediatrics2022
Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease.
Article in Clinical and experimental pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Guideline for the diagnosis and treatment of incomplete Kawasaki disease in children in China.BMC pediatrics · 2024Guideline
- Infectious triggers in IgA vasculitis in children: current evidence, causal attribution and immunopathogenic mechanisms.Rheumatology international · 2026Review
- Infliximab for intravenous immunoglobulin-resistant Kawasaki disease complicated with cholestatic hepatitis: a case report and discussion on coronary artery aneurysm prevention.Frontiers in pediatrics · 2026Article
- An etiopathogenesis of juvenile idiopathic arthritis: the protein-homeostasis-system hypothesis.Frontiers in pediatrics · 2026Review
- A new immunological paradigm for diseases: the protein-homeostasis-system hypothesis.Frontiers in immunology · 2026Review
- A Unified Pathogenesis of Allergic Diseases; The Protein-Homeostasis-System Hypothesis.International journal of molecular sciences · 2025Review
- Prediction model for severe mycoplasma pneumoniae pneumonia and analysis of macrolide-resistance in children: a case-control study.Italian journal of pediatrics · 2025Article
- Observational
- Significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.BMC pulmonary medicine · 2024Article
- Comparison of early characteristics of multisystemic inflammatory syndrome and Kawasaki disease in children and the course of Kawasaki disease in the pandemic.BMC pediatrics · 2024Article
- Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity.European journal of pediatrics · 2023Article
- Multisystem inflammatory syndrome in children and Kawasaki disease; comparison of their clinical findings and one-year follow-up-a cross-sectional study.Italian journal of pediatrics · 2023Article
- Analysis of cytokine levels, cytological findings, and MP-DNA level in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia.Immunity, inflammation and disease · 2023Article
- How multisystem inflammatory syndrome in children discriminated from Kawasaki disease: a differentiating score based on an inception cohort study.Clinical rheumatology · 2023Article
- Clinical Signs of Kawasaki Disease from the Perspective of Epithelial-to-Mesenchymal Transition Recruiting Erythrocytes: A Literature Review.Reviews in cardiovascular medicine · 2023Review
- Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.Frontiers in immunology · 2023Review
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- Research trends on causes of Kawasaki disease in the COVID-19 era: focus on viral infections.Clinical and experimental pediatrics · 2023Article
- Common immunopathogenesis of central nervous system diseases: the protein-homeostasis-system hypothesis.Cell & bioscience · 2022Review
- Analysis of Gene Single Nucleotide Polymorphisms in COVID-19 Disease Highlighting the Susceptibility and the Severity towards the Infection.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, a novel multisystem inflammatory syndrome in children (MIS-C) has been reported worldwide since the first cases were reported in Europe in April 2020. MIS-C is temporally associated with severe acute respiratory syndrome coronavirus 2 infection and shows Kawasaki disease (KD)-like features. The epidemiological and clinical characteristics in COVID-19, KD, and MIS-C differ, but severe cases of each disease share similar clinical and laboratory findings such as a protracted clinical course, multiorgan involvement, and similar activated biomarkers. These findings suggest that a common control system of the host may act against severe disease insult. To solve the enigmas, we proposed the protein-homeostasis-system hypothesis in that every disease involves etiological substances and the host's immune system controls them by their size and biochemical properties. Also, it is proposed that the etiological agents of KD and MIS-C might be certain strains in the microbiota of human species and etiological substances in severe COVID-19, KD, and MIS-C originate from pathogen-infected cells. Since disease severity depends on the amounts of inflammation-inducing substances and corresponding immune activation in the early stage of the disease, an early proper dose of corticosteroids and/or intravenous immunoglobulin (IVIG) may help reduce morbidity and possibly mortality among patients with these diseases. Corticosteroids are low cost and an analogue of host-origin cortisol among immune modulators. This study's findings will help clinicians treating severe COVID-19, KD, and MIS-C, especially in developing countries, where IVIG and biologics supplies are insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.